Welcome to LookChem.com Sign In|Join Free

CAS

  • or

381-97-5

Post Buying Request

381-97-5 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

381-97-5 Usage

General Description

3,3,3-Trifluoro-2-Methylpropanoic acid, also known as alpha,alpha,alpha-Trifluoro-2-methylpropionic acid, is a chemical compound with the molecular formula C4H5F3O2. This substance often appears as a colorless liquid under normal conditions, and has a molar mass of 134.07 g·mol?1. It is known for possessing properties such as a strong odour, being highly corrosive, and having the ability to cause severe burns and eye damage. Known for its acid strength and solvent properties, it is frequently applied in various industrial applications like the synthesis of pharmaceuticals, optical materials and more. Special precautions should be taken while handling, due to its potential health hazards.

Check Digit Verification of cas no

The CAS Registry Mumber 381-97-5 includes 6 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 3 digits, 3,8 and 1 respectively; the second part has 2 digits, 9 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 381-97:
(5*3)+(4*8)+(3*1)+(2*9)+(1*7)=75
75 % 10 = 5
So 381-97-5 is a valid CAS Registry Number.

381-97-5SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 19, 2017

Revision Date: Aug 19, 2017

1.Identification

1.1 GHS Product identifier

Product name 3,3,3-Trifluoro-2-methylpropanoic acid

1.2 Other means of identification

Product number -
Other names 2-trifluoromethylpropanoic acid

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:381-97-5 SDS

381-97-5Downstream Products

381-97-5Relevant articles and documents

Lipase mediated preparation of the enantiomers of 3,3,3-trifluoro-2- methylpropanoic acid

Beier, Petr,Z. Slawin, Alexandra M.,O'Hagan, David

, p. 2447 - 2449 (2004)

Both enantiomers of 3,3,3-trifluoro-2-methylpropanoic acid were prepared by a lipase mediated kinetic resolution of the racemate. The preparation of both enantiomers of 3,3,3-trifluoro-2-methylpropanoic acid by a lipase mediated kinetic resolution of the

Low-Flammable Parahydrogen-Polarized MRI Contrast Agents

Ariyasingha, Nuwandi M.,Chekmenev, Eduard Y.,Chukanov, Nikita V.,Gelovani, Juri G.,Joalland, Baptiste,Koptyug, Igor V.,Kovtunov, Kirill V.,Nantogma, Shiraz,Salnikov, Oleg G.,Younes, Hassan R.

, p. 2774 - 2781 (2021/01/18)

Many MRI contrast agents formed with the parahydrogen-induced polarization (PHIP) technique exhibit biocompatible profiles. In the context of respiratory imaging with inhalable molecular contrast agents, the development of nonflammable contrast agents would nonetheless be highly beneficial for the biomedical translation of this sensitive, high-throughput and affordable hyperpolarization technique. To this end, we assess the hydrogenation kinetics, the polarization levels and the lifetimes of PHIP hyperpolarized products (acids, ethers and esters) at various degrees of fluorine substitution. The results highlight important trends as a function of molecular structure that are instrumental for the design of new, safe contrast agents for in vivo imaging applications of the PHIP technique, with an emphasis on the highly volatile group of ethers used as inhalable anesthetics.

PHENYL SUBSTITUTED PYRAZOLES AS MODULATORS OF RORgT

-

Paragraph 0455, (2020/01/09)

The present invention comprises compounds of Formula I. wherein: R1, R3, R4, R5, R6, R7, R8, and Q are defined in the specification. The invention also comprises a method of treating or ameliorating a ROR-γ-t mediated syndrome, disorder or disease, including wherein the syndrome, disorder or disease is selected from the group consisting of rheumatoid arthritis, psoriatic arthritis, and psoriasis. The invention also comprises a method of modulating RORγt activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 381-97-5